Pfizer-birthed Ziarco raises $33m for skin drugs

A company formed by Pfizer's former head of allergy and respiratory research in Sandwich, UK, has raised $33.1m in a series B round to fund development of novel candidates to treat atopic dermatitis and psoriasis. Ziarco, headed by Mike Yeadon, will use the funds to complete proof of concept Phase II trials of its two lead candidates.